Physician profile
Nathan Borgfeld
NPI 1467801779
$857.58
in general payments reported to CMS, 2019-2025
15 companies · $59.77 in 2025
The $59.77 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $44.65 · 2021: $85.27 · 2022: $145 · 2023: $56.35 · 2024: $318 · 2025: $59.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $248.10 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $126.14 | 2020-2024 | Mounjaro, Jardiance |
| Genentech USA, INC. | $124.35 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $72.13 | 2021-2023 | Breztri |
| Access Pro Medical, LLC | $48.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.75 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.25 | 2022 | |
| Abbvie INC. | $31.07 | 2024 | |
| Nevro Corp. | $27.72 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $23.92 | 2019 | |
| Glaxosmithkline, LLC. | $22.49 | 2025 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $14.98 | 2025 | Gemtesa |
| Amgen INC. | $14.81 | 2023 | Evenity, Prolia |
| Abbott Laboratories | $14.75 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.01 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Borgfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.